Cogent Biosciences, Inc. COGT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s cash & equivalents?
- Cogent Biosciences, Inc. (COGT) reported cash & equivalents of $241.21M in Q1 2026.
- How has Cogent Biosciences, Inc.'s cash & equivalents changed year-over-year?
- Cogent Biosciences, Inc.'s cash & equivalents increased by 91.4% year-over-year, from $126M to $241.21M.
- What is the long-term trend for Cogent Biosciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s cash & equivalents has grown at a 5.2% compound annual growth rate (CAGR), from $242.19M to $312.01M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.